685 related articles for article (PubMed ID: 10996576)
21. Salmon calcitonin nasal spray treatment for postmenopausal women after hip fracture with total hip arthroplasty.
Peichl P; Marteau R; Griesmacher A; Kumpan W; Schedl R; Prosquil E; Fasol P; Bröll H
J Bone Miner Metab; 2005; 23(3):243-52. PubMed ID: 15838628
[TBL] [Abstract][Full Text] [Related]
22. Effects of 5-year treatment with elcatonin and alfacalcidol on lumbar bone mineral density and the incidence of vertebral fractures in postmenopausal women with osteoporosis: a retrospective study.
Iwamoto J; Takeda T; Ichimura S; Uzawa M
J Orthop Sci; 2002; 7(6):637-43. PubMed ID: 12486466
[TBL] [Abstract][Full Text] [Related]
23. A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers.
Trovas GP; Lyritis GP; Galanos A; Raptou P; Constantelou E
J Bone Miner Res; 2002 Mar; 17(3):521-7. PubMed ID: 11874243
[TBL] [Abstract][Full Text] [Related]
24. Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study.
Silverman SL; Chines AA; Kendler DL; Kung AW; Teglbjærg CS; Felsenberg D; Mairon N; Constantine GD; Adachi JD;
Osteoporos Int; 2012 Jan; 23(1):351-63. PubMed ID: 21779819
[TBL] [Abstract][Full Text] [Related]
25. Acute effects of calcitonin nasal spray on serum C-telopeptide of type 1 collagen (CTx) levels in elderly osteopenic women with increased bone turnover.
Srivastava AK; Libanati C; Hohmann O; Kriegman A; Baylink DJ
Calcif Tissue Int; 2004 Dec; 75(6):477-81. PubMed ID: 15365658
[TBL] [Abstract][Full Text] [Related]
26. Clinical outcome of salmon calcitonin nasal spray treatment in postmenopausal women after total hip arthroplasty.
Peichl P; Griesmacher A; Kumpan W; Schedl R; Prosquil E; Bröll H
Gerontology; 2005; 51(4):242-52. PubMed ID: 15980653
[TBL] [Abstract][Full Text] [Related]
27. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
Liberman UA; Weiss SR; Bröll J; Minne HW; Quan H; Bell NH; Rodriguez-Portales J; Downs RW; Dequeker J; Favus M
N Engl J Med; 1995 Nov; 333(22):1437-43. PubMed ID: 7477143
[TBL] [Abstract][Full Text] [Related]
28. Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy.
Meunier PJ; Sebert JL; Reginster JY; Briancon D; Appelboom T; Netter P; Loeb G; Rouillon A; Barry S; Evreux JC; Avouac B; Marchandise X
Osteoporos Int; 1998; 8(1):4-12. PubMed ID: 9692071
[TBL] [Abstract][Full Text] [Related]
29. The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. A randomized, controlled trial.
Reginster JY; Meurmans L; Zegels B; Rovati LC; Minne HW; Giacovelli G; Taquet AN; Setnikar I; Collette J; Gosset C
Ann Intern Med; 1998 Jul; 129(1):1-8. PubMed ID: 9652994
[TBL] [Abstract][Full Text] [Related]
30. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
Chesnut CH; Skag A; Christiansen C; Recker R; Stakkestad JA; Hoiseth A; Felsenberg D; Huss H; Gilbride J; Schimmer RC; Delmas PD;
J Bone Miner Res; 2004 Aug; 19(8):1241-9. PubMed ID: 15231010
[TBL] [Abstract][Full Text] [Related]
31. Nasal salmon calcitonin blunts bone microstructure alterations in healthy postmenopausal women.
Rizzoli R; Sigaud A; Azria M; Herrmann FR
Osteoporos Int; 2015 Jan; 26(1):383-93. PubMed ID: 25566730
[TBL] [Abstract][Full Text] [Related]
32. Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures. A double blind, placebo-controlled clinical study.
Lyritis GP; Paspati I; Karachalios T; Ioakimidis D; Skarantavos G; Lyritis PG
Acta Orthop Scand Suppl; 1997 Oct; 275():112-4. PubMed ID: 9385283
[TBL] [Abstract][Full Text] [Related]
33. Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study.
Chesnut CH; Majumdar S; Newitt DC; Shields A; Van Pelt J; Laschansky E; Azria M; Kriegman A; Olson M; Eriksen EF; Mindeholm L
J Bone Miner Res; 2005 Sep; 20(9):1548-61. PubMed ID: 16059627
[TBL] [Abstract][Full Text] [Related]
34. Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis.
Thamsborg G; Jensen JE; Kollerup G; Hauge EM; Melsen F; Sorensen OH
Bone; 1996 Feb; 18(2):207-12. PubMed ID: 8833216
[TBL] [Abstract][Full Text] [Related]
35. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk.
Boonen S; Adachi JD; Man Z; Cummings SR; Lippuner K; Törring O; Gallagher JC; Farrerons J; Wang A; Franchimont N; San Martin J; Grauer A; McClung M
J Clin Endocrinol Metab; 2011 Jun; 96(6):1727-36. PubMed ID: 21411557
[TBL] [Abstract][Full Text] [Related]
36. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
Miller PD; Hattersley G; Riis BJ; Williams GC; Lau E; Russo LA; Alexandersen P; Zerbini CA; Hu MY; Harris AG; Fitzpatrick LA; Cosman F; Christiansen C;
JAMA; 2016 Aug; 316(7):722-33. PubMed ID: 27533157
[TBL] [Abstract][Full Text] [Related]
37. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).
Sugimoto T; Matsumoto T; Hosoi T; Miki T; Gorai I; Yoshikawa H; Tanaka Y; Tanaka S; Fukunaga M; Sone T; Nakano T; Ito M; Matsui S; Yoneda T; Takami H; Watanabe K; Osakabe T; Okubo N; Shiraki M; Nakamura T
Osteoporos Int; 2015 Feb; 26(2):765-74. PubMed ID: 25403903
[TBL] [Abstract][Full Text] [Related]
38. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.
Reginster J; Minne HW; Sorensen OH; Hooper M; Roux C; Brandi ML; Lund B; Ethgen D; Pack S; Roumagnac I; Eastell R
Osteoporos Int; 2000; 11(1):83-91. PubMed ID: 10663363
[TBL] [Abstract][Full Text] [Related]
39. Salmon calcitonin reduces vertebral fracture rate in postmenopausal crush fracture syndrome.
Rico H; Hernandez ER; Revilla M; Gómez-Castresana F
Bone Miner; 1992 Feb; 16(2):131-8. PubMed ID: 1576488
[TBL] [Abstract][Full Text] [Related]
40. Increase of axial and appendicular trabecular and cortical bone density in established osteoporosis with intermittent nasal salmon calcitonin therapy.
Peichl P; Rintelen B; Kumpan W; Bröll H
Gynecol Endocrinol; 1999 Feb; 13(1):7-14. PubMed ID: 10368793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
